BioSpace News Archive

NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that it intends to offer and sell, subject to market and other conditions, $150.0 million of shares of its common stock in an underwritten public offering pursuant to NanoString’s shelf registration statement. In connection with this offering, NanoString expects to grant the underwriters

Medtronic plc announced that Omar Ishrak has decided not to stand for re-election at the Annual General Meeting in December and will retire as Executive Chairman and Chairman of its Board of Directors effective December 11, 2020.

Complete third quarter 2020 financial results will be announced on Tuesday, October 27, 2020 Preliminary third quarter 2020 product revenue ranging from $274 million to $278 million Full-year guidance for 2020 product revenue ranging from $1,124 million to $1,128 million

Lumos Diagnostics , a rapid point-of-care diagnostics company, has closed an oversubscribed AU$25 million pre-IPO capital raise, ahead of an anticipated 2021 Australian Securities Exchange (ASX) listing. The funding will enable Lumos, headquartered in Melbourne, to continue to build its high-growth rapid diagnos

Eisai Co., Ltd. announced today that it has entered into a joint research agreement with four research organizations (KAN Research Institute, National Center for Global Health and Medicine, Nagasaki University, and Yokohama City University) in Japan concerning the “Development of Therapeutics to Prevent the Aggravation of the Novel Coronavirus Infectious Disease (COVID-19)”

TLC announced the receipt of ethical and scientific approval from the Bellberry Human Research Ethics Committee in Australia for the Company’s Phase I clinical trial of TLC19 Hydroxychloroquine Liposome Inhalation Suspension for Coronavirus disease 2019.

SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, announced today that it has commenced an underwritten public offering of $150,000,000 of shares of its common stock. All of the shares in the offering will be sold by SpringWorks. In addition, SpringWorks expects to grant the underwriters a 30-day option to pu

AmerisourceBergen Corporation (NYSE: ABC) today announced that it plans to release its results for the Fourth Quarter Fiscal 2020 on Thursday, November 5, 2020, prior to the opening of trading on the New York Stock Exchange

- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that John Houston, Ph.D., President and Chief Executive Officer, will present a keynote plenary session at the 3rd Annual Targeted Protein Degradation Summit being held virtually October 14-15, 2020. The presentation will reflect on Arvinas’ advances in its PROTAC® platform and introduce new

Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, announces the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976,